Recruiting
Investigational
A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
Investigational
- Substances:–
Countries:
Czechia
Czechia- Participants:18–64 years
Find therapies in clinical trials near you
- recruiting
- 3 962
- countries
- 28
- conditions
- 2 101
3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today
76 trials match your criteria
Recruiting
Psoriatic arthropathy
RecruitingInvestigational
Long-Term Safety and Efficacy of Zasocitinib in Adults with Active Psoriatic Arthritis
Investigational
- Disease:Psoriatic arthropathy
- Substances:Zasocitinib
Countries:Czechia
Czechia- Participants:18–64 years · 65+ years
- Substances:Zasocitinib
Recruiting
Cardiac failure+1
RecruitingInvestigational
Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity
Investigational
- Disease:Cardiac failureObesity
- Substances:–
Countries:Czechia
Czechia- Participants:18–64 years · 65+ years
Recruiting
Cardiovascular disorder+1
RecruitingInvestigational
Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk
Investigational
- Disease:Cardiovascular disorderHypertension
- Substances:ZILEBESIRAN
Countries:Czechia
Czechia- Participants:18–64 years · 65+ years
- Substances:ZILEBESIRAN
Recruiting
Migraine
RecruitingRegistered drug
Study of IncobotulinumtoxinA injections compared to placebo for prevention of episodic migraine attacks
Registered drug
- Disease:Migraine
- Substances:Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
Countries:Czechia
Czechia- Participants:18–64 years · 65+ years
- Substances:Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
Recruiting
Migraine
RecruitingRegistered drug
Study of incobotulinumtoxinA injections for prevention of chronic migraine in adult patients
Registered drug
- Disease:Migraine
- Substances:Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
Countries:Czechia
Czechia- Participants:18–64 years · 65+ years
- Substances:Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
Recruiting
Arteriosclerosis
RecruitingInvestigational
Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it
Investigational
- Disease:Arteriosclerosis
- Substances:–
Countries:Czechia
Czechia- Participants:18–64 years · 65+ years
Recruiting
Psoriatic arthropathy
RecruitingRegistered drug
Study of Zasocitinib and Apremilast for Adults with Active Psoriatic Arthritis Who Have Not Used Biologic Medicines
Registered drug
- Disease:Psoriatic arthropathy
- Substances:ApremilastZasocitinib
Countries:Czechia
Czechia- Participants:18–64 years · 65+ years
- Substances:Apremilast
Recruiting
Colitis ulcerative
RecruitingInvestigational
Study on Eltrekibart and Mirikizumab for Adults with Moderate to Severe Ulcerative Colitis
Investigational
- Disease:Colitis ulcerative
- Substances:MirikizumabHumanised Igg4 Kappa Monoclonal Antibody Against Cxcl1, Cxcl2, Cxcl3, Cxcl5, Cxcl6, Cxcl7 And Cxcl8
Countries:Czechia
Czechia- Participants:18–64 years · 65+ years
- Substances:Mirikizumab
Recruiting
Cardiac failure
RecruitingRegistered drug
Study on BI 690517 and Empagliflozin for Patients with Heart Failure and Preserved Ejection Fraction
Registered drug
- Disease:Cardiac failure
- Substances:Bi 690517Empagliflozin
Countries:Czechia
Czechia- Participants:18–64 years · 65+ years
- Substances:Bi 690517
Recruiting
Squamous cell carcinoma of head and neck
RecruitingRegistered drug
Study of Dostarlimab After Chemoradiation for Adults with Advanced Unresected Head and Neck Cancer
Registered drug
- Disease:Squamous cell carcinoma of head and neck
- Substances:Dostarlimab
Countries:Czechia
Czechia- Participants:18–64 years · 65+ years
- Substances:Dostarlimab
Recruiting
Crohn's disease
RecruitingInvestigationalNo placebo
Study on the Long-Term Effects and Safety of Mirikizumab for Patients with Crohn's Disease
InvestigationalNo placebo
- Disease:Crohn's disease
- Substances:Mirikizumab
Countries:Czechia
Czechia- Participants:18–64 years · 65+ years
- Substances:Mirikizumab